Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 25'th Apr 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
04:05pm, Thursday, 24'th Apr 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting
07:00am, Wednesday, 23'rd Apr 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript
07:46pm, Thursday, 27'th Mar 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
04:05pm, Thursday, 27'th Mar 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
04:05pm, Wednesday, 26'th Mar 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
08:00am, Friday, 07'th Mar 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
04:05pm, Thursday, 20'th Feb 2025
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced p
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announ
Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
07:00am, Monday, 13'th Jan 2025
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
09:00am, Friday, 03'rd Jan 2025
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced pl
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
04:30pm, Monday, 23'rd Dec 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today an
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
08:00am, Thursday, 19'th Dec 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powere
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
02:25pm, Thursday, 31'st Oct 2024
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced po
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
09:42pm, Wednesday, 30'th Oct 2024
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Of
